VKTX

Analyst Note: Viking Therapeutics, Inc. (VKTX)

Date: June 13, 2026

1. Structural Readiness The stock is currently trading at $36.99, situated within a constructive base formation that has been tightening over recent sessions. The setup is currently in a "forming" state, indicating that the structural prerequisites for a continuation are in place, though a confirmed breakout has not yet been triggered. To transition from a forming base to a confirmed breakout, the price must clear the resistance level of $43.15. The current price represents a pre-breakout entry opportunity, with an aggressive entry point noted at $32.66. While the base is forming, historical data suggests that approximately 69% of setups with this specific structure eventually break out, providing a partial but positive readiness signal. The current daily volatility, measured by the Average True Range (ATR), is elevated at 5.0%, which falls within the historical "high" volatility bucket (4–6%), suggesting significant price movement potential as the structure resolves.

2. The Thesis Layer The primary secular thesis driving this name is exposure to the Biotech & GLP-1 / Metabolic sector. Viking Therapeutics is a direct beneficiary of this theme, positioned as a high-conviction growth leader within the obesity and metabolic disorder space. The company is not merely a peripheral player but is developing a dual-agonist candidate (VK2735) that targets the same market drivers as industry leaders, offering a potential best-in-class alternative. As of this date, the company is a member of one primary secular theme with high confidence in its direct relevance. The narrative is supported by the broader market context where major pharmaceutical players are actively seeking to expand their metabolic portfolios, creating a favorable environment for clinical-stage biotechs with validated data.

3. The Business Viking Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. The core of the business model relies on the advancement of its lead asset, VK2735, a dual agonist of the GLP-1 and GIP receptors, developed in both subcutaneous and oral formulations.

As of the most recent earnings transcript dated February 11, 2026, and subsequent SEC filings, the company has made significant progress in its clinical pipeline:

• Clinical Progress: The company announced in November 2025 that the VANQUISH-1 study was fully enrolled, exceeding the 4,500 patient target. Enrollment in the companion VANQUISH-2 study was completed in March 2026. Additionally, the maintenance study enrollment was completed in January 2026, with results expected in the third quarter of 2026.
• Oral Formulation: Following positive Phase 2 VENTURE-Oral Dosing trial results announced in August 2025, which showed up to 12.2% body weight reduction, management expects to initiate Phase 3 oral dosing studies in the fourth quarter of 2026 (per the April 30, 2026 filing) or third quarter of 2026 (per the February 11 transcript).
• Pipeline Expansion: In April 2026, the company filed an IND for VK3019, a novel amylin agonist, with Phase 1 initiation planned for the second quarter of 2026.
• Commercial Readiness: To support potential commercialization, Viking signed a comprehensive manufacturing agreement with CordenPharma in March 2025. This agreement secures large-scale supply of active pharmaceutical ingredients (API) and fill-and-finish capacity for both subcutaneous and oral formulations. The terms include prepayments to be made from 2026 to 2028, which will be credited against future orders.
• Financial Position: As of December 31, 2025, the company held $706 million in cash, cash equivalents, and short-term investments, down from $903 million the prior year, reflecting the capital deployment required for these advanced clinical programs.

4. Archetype and Conviction Viking Therapeutics fits the Growth Leader archetype. The company is transitioning from a pure clinical-stage entity to one with near-term catalysts (Phase 3 initiation and data readouts) that could drive significant rerating. The financial spine indicates continued losses with forward consensus EPS of -4.75 for FY1 and -4.77 for FY2, which is standard for a clinical-stage biotech in the late-phase development window.

The conviction is supported by:

• Thesis Strength: Direct exposure to the high-growth GLP-1 market with a differentiated dual-agonist mechanism.
• Evidence Quality: Strong clinical data from Phase 2 (12.2% weight loss) and successful enrollment of large Phase 3 trials (VANQUISH-1 and -2).
• Structural Quality: The stock is trading in a high-volatility environment (5.0% ATR) with a constructive base, suggesting active institutional interest and liquidity.
• Rerating Potential: The initiation of Phase 3 oral studies and the filing for the amylin agonist (VK3019) provide a multi-catalyst runway.

5. Invalidation and Gaps What would Strengthen the Case:

• Positive top-line data from the Phase 3 VANQUISH-1 or VANQUISH-2 studies.
• Successful initiation and early data from the Phase 3 oral VK2735 program.
• Positive interim data from the Phase 1 VK3019 study.
• Clearer guidance on the timing of the Phase 3 oral study initiation if it shifts earlier than the Q4 2026 expectation.

What would Invalidate the Case:

• Negative or inconclusive results from the ongoing Phase 3 trials (VANQUISH-1 or -2).
• Regulatory delays or rejection of the IND for VK3019.
• A significant deterioration in the cash runway that forces dilutive financing at unfavorable terms.
• A failure to clear the $43.15 resistance level with a subsequent breakdown below the base structure.

Gaps in the Evidence Base:

• Specific Phase 3 Data: While enrollment is complete, the actual efficacy and safety data from the Phase 3 trials have not yet been released as of June 13, 2026. The market is currently pricing in expectations, not confirmed outcomes.
• Oral Formulation Timeline: There is a slight discrepancy in management expectations between the February transcript (Q3 2026 initiation) and the April filing (Q4 2026 initiation) regarding the Phase 3 oral study. The exact timing remains a variable.
• Competitive Landscape: While the company is positioned against Eli Lilly and Novo Nordisk, specific comparative data regarding head-to-head efficacy or tolerability against approved competitors is not yet available in the public record as of this date.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Successful completion of enrollment in two major Phase 3 trials (VANQUISH-1 and -2); positive Phase 2 oral data showing 12.2% weight loss; secured manufacturing supply agreement with CordenPharma for commercial readiness. Key risks: Potential negative Phase 3 clinical results; timeline slippage on oral Phase 3 initiation; cash burn rate relative to remaining runway; competitive pressure from established GLP-1 leaders. Sizing hint: Position size should reflect the binary nature of the upcoming Phase 3 data readouts, utilizing the current volatility to manage entry risk. Expected path: Management expects to report Phase 3 maintenance results in Q3 2026 and initiate Phase 3 oral studies in Q4 2026, with the stock likely reacting to these milestones. Expected horizon: 6 to 12 months for the primary catalysts to resolve. Failure mode to watch: A failure to clear the $43.15 resistance level combined with a breakdown in the base structure, signaling a loss of momentum ahead of data.